News EU approves Ipsen's Cabometyx in first line kidney cancer Drug looks set to become core part of Ipsen's cancer offering
News Roche’s Tecentriq + Avastin racks up another combination suc... Roche has produced new data showing a combination of Tecentriq and older drug Avastin is more effective than standard therapy for delaying progression in kidney cancer patients.
News NICE says no to Ipsen’s kidney cancer drug NICE has issued draft guidance which rejects Ipsen's Cabometyx for NHS use in previously treated advanced renal cell carcinoma (RCC).
News NICE recommends Novartis kidney cancer drug Afinitor finally recommended after rejection in 2011.
News Ipsen/Exelixis' drug approved in EU for kidney cancer Cabometyx secures new indication in renal cell carcinoma.
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
